Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza – Tender Specifications – Lot 2 OJ/2021/DPR/12924  (primary and secondary outcomes, as defined in the study protocol), number of  vaccinations performed (including information on brand, number of first and  second doses, as defined in the study protocol). The dataset to be delivered should  use a format compatible with TESSy.  The final format of the deliverable shall be agreed during the monthly conference  calls with ECDC. Cumulative data and datasets should be presented covering the  period since the beginning of data collection showing total and per country  specifications.  The contractor is expected to supervise and coordinate the data collection from the  study sites and to work closely with ECDC to establish a data flow from the countries  to ECDC. The contractor will plan the data collection ensuring compatibility with The  European Surveillance System (TESSy) metadata, TESSy reporting protocol, and  considering potential interaction with other vaccine related data collected in TESSy.  The validation of the datasets will be performed in close collaboration with the study  sites and will be aimed to build capacity and foster a progressive improvement of  data reported by the study sites over the course of the project. Communication  between the contractor and the study sites to validate the data will take place using  principles agreed between the contractor and ECDC and periodically revisited.  DL 2.2.6. Regular  laboratory data  update  Production of regular laboratory results summary table to ECDC specifying the  number of laboratory specimens processed and tested and the proportion of  positive samples by study site, stratified by key variables. The EU/EEA protocol on vaccine effectiveness studies in health care workers, in its  current version, includes vaccine effectiveness against lab-confirmed SARS-CoV-2  infection independent of symptoms as a primary outcome.  On a monthly basis  Word, Power Point 